Hypothesized pharmacogenomic and medication influences on tetrahydrocannabinol and cannabidiol metabolism in a cohort of unselected oral cannabis users
2025

Influences on THC and CBD Metabolism in Cannabis Users

Sample size: 71 publication Evidence: moderate

Author Information

Author(s): Wright Jessica A., Huang Linda, Katamesh Basant E., Yadav Siddhant, Singla Abhinav, Vincent Ann

Primary Institution: Mayo Clinic College of Medicine and Science

Hypothesis

How do atypical genetic variants and medications influence the metabolism of THC and CBD in oral cannabis users?

Conclusion

The study reveals potential alterations in THC and CBD metabolism due to genetic variants and medications, highlighting the need for awareness among clinicians.

Supporting Evidence

  • 71 patients confirmed oral cannabis use.
  • 10 patients had no atypical variants.
  • 31 patients had atypical variants in CYP2C9.
  • 37 patients had atypical variants in CYP2C19.
  • 5 patients were taking medications that could interact with THC.
  • 8 patients were taking medications that could interact with CBD.

Takeaway

Some people process cannabis differently because of their genes and the medications they take, which can change how THC and CBD work in their bodies.

Methodology

A retrospective chart review was conducted on patients who completed pharmacogenomic testing and reported oral cannabis use.

Potential Biases

Self-reporting bias and potential missing data due to incomplete medical records.

Limitations

The study relied on self-reported cannabis use, which may lead to underreporting, and lacked detailed documentation on cannabis product composition.

Participant Demographics

Average age of 68.5 years, predominantly white women (73.2%), with 94.4% being Caucasian.

Digital Object Identifier (DOI)

10.1186/s42238-024-00256-6

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication